Latest in Cardiology from ACC.org

• ViVA: Vericiguat For the Treatment of Coronary Vasospasm
  Vericiguat did not improve peripheral vasodilator function or anginal symptoms in patients with angina and no obstructive coronary arteries (ANOCA) and with epicardial and/or microvascular vasospasm.
• CMR GUIDE: ICD vs. ILR in Reducing Sudden Cardiac Death and HSVA
  Implantation of an ICD did not significantly reduce sudden cardiac death (SCD) or hemodynamically significant ventricular arrhythmia (HSVA) compared with an implantable loop recorder (ILR) in patients with an LVEF of 36% to 50% and myocardial scar, based on results from the CMR GUIDE trial...
• ACACIA-HCM: Aficamten vs. Placebo in Treating Symptomatic Non-Obstructive HCM
  Patients with symptomatic nonobstructive hypertrophic cardiomyopathy (HCM) who were treated with aficamten vs. placebo saw significantly greater improvement in exercise capacity and self-reported health status at 36 weeks, according to findings from the ACACIA-HCM trial...
• POET-II: Tailored Antibiotic Strategy vs. Standard Therapy For Treating Left-Sided Infective Carditis
  In patients with left-sided infective endocarditis a clinical response-tailored antibiotic strategy shortened antibiotic duration by two weeks compared with standard therapy, with no major safety concerns, based on findings from the POET-II study...
• SINGLE-AF: DOAC Therapy vs. No Anticoagulation in AFib Patients at Intermediate Risk For Stroke
  In patients with atrial fibrillation (AFib) at intermediate risk for stroke, DOAC therapy resulted in a lower risk of stroke, systemic embolism, major bleeding or death from cardiovascular causes at 24 months compared with no anticoagulation.